Amping up HIV antibodies

August 26, 2021

Publication type

Review Article



Volume and Number

Vol. 372 Issue 6549 Starting Page: 1397

Burton, Dennis R.


The recent results (1) from the Antibody Mediated Prevention (AMP) study are a landmark in AIDS research. They show that a broadly neutralizing antibody (bnAb) can protect humans against infection with sensitive strains of HIV. BnAbs, antibodies that can neutralize a large fraction of globally circulating HIV strains, are the focus of many HIV vaccine efforts and of strategies to prevent or treat HIV by passive immunization (infusion with antibodies). This focus results from the enormous strain variability of HIV—only bnAbs can hope to counter this variability. The results have profound implications for HIV vaccine design and for the use of passively administered bnAbs. Within the context of earlier animal model studies, the AMP study results provide insight into the factors that are important for antibody protection against HIV.

The following URLS link to the full text and abstract of this article published in Science:



Full text: